Introduction
Insulin-like growth factor I and II (IGF-I and IGF-II) associate with specific IGF binding proteins (IGFBPs) present in plasma and extracellular fluids that can modulate the anabolic effects of these peptides. IGF-I has been shown to increase IGFBP concentrations in vivo and in vitro, but the mechanism and significance of this action are unknown. We examined these issues using normal and simian virus 40-transformed adult human fibroblasts (SV40-HF) in culture. Treatment with IGF-I markedly stimulated the appearance of IGFBP-3 (42/38 kD doublet), a 36 kD IGFBP, and 28-32 kD IGFBPs in the medium of these cells, as assessed by Western ligand blotting, IGF-I decreased levels of 24 kD IGFBP in normal HF cultures. The IGF-I-induced change in IGFBP levels was not a type I IGF receptor-mediated effect on IGFBP synthesis because (a) high concentrations of insulin did not mimic IGF-I's effect; (b) IGF-II and IGF-I analogues having reduced affinity for the IGF-I receptor were equipotent with IGF-I in increasing medium IGFBPs; (c) IQAYLJIGF-I, an IGF-I analogue having normal receptor affinity and decreased affinity for IGFBPs, had no effect; and (d) aIR-3, a monoclonal antibody specific for the type I IGF receptor, did not block IGF-I-stimulated increases in IGFBPs. In physiological studies, preincubation with 1 nM IGF-I had no effect on type I IGF receptor binding in normal HF and SV40-HF. In contrast, preincubation of cells with an equivalent concentration of IQAYLiIGF-I downregulated the receptors 40-50%. Changes in cell surface receptor number were reflected in cell responsiveness to IGF-I-stimulated 1H1-thymidine incorporation and VHlaminoisobutyric acid uptake.
In conclusion, IGF-I regulates the availability of specific IGFBPs in cultured human fibroblasts by a novel receptor-independent mechanism. Rapid changes in levels of soluble IGFBPs as a direct response to extracellular IGF-I, in turn, modulate IGF-I peptide and receptor interaction, and may constitute an important level of control in IGF cellular physiology. The insulin-like growth factors I and II (IGF-I, IGF-II) are growth hormone (GH)'-dependent peptides ancestrally related to insulin that have potent growth-promoting and insulin-like effects in vivo and in vitro (1) . Unlike insulin, these peptides associate with distinct proteins present in serum and other biological fluids, as well as in medium conditioned by cultured cells (2) . Multiple insulin-like growth factor binding proteins (IGFBPs) have been identified, and full amino acid sequence has been determined for four of these proteins (3) (4) (5) (6) (7) (8) (9) .
At present, the factors regulating IGFBP synthesis and secretion are not completely understood. IGFBP-3 has been referred to as the GH-dependent IGFBP; however, recent evidence suggest that in vivo IGF-I mediates GH-associated increases in IGFBP-3 levels (10, 11) . Subcutaneous infusion of IGF-I in healthy adults also raises serum levels of IGFBP-2 (12). Moreover, IGF-I stimulates the release of various IGFBPs, including IGFBP-3, in cultured cells (13) (14) (15) (16) (17) (18) IGFs were iodinated by a modification ofthe chloramine T method to a specific activity of 150-300 MCi/Mg (26) . Cell cultures. Dermal fibroblasts from normal adult donors (GM03652A and GM00037D) and SV40-transformed GM00037D cells (GM00637D) were purchased from the Human Genetic Mutant Cell Repository (Camden, NJ). Fibroblasts were cultured in DME supplemented with 100 U/ml penicillin, 100 Mg/ml streptomycin, and 4 mM glutamine, and containing 10% supplemented calf serum (HyClone Laboratories, Logan, UT).
Conditioned medium. Cells were detached by trypsinization and plated in 24-multiwells (Costar, Data Packaging Corp., Cambridge, MA). At confluency, fibroblasts were washed twice and preincubated in a 1:1 mixture by volume of Waymouth's medium:DME plus 0.1% BSA serum-free medium (SFM) for 24 h. The cells were then washed and the medium changed to 0.5 ml SFM±experimental additions for the indicated times. At the end of the incubation period, the conditioned medium was centrifuged at 2000 g, 4C for 30 min and frozen at -20'C. At the time of media collection, cell counts were determined on triplicate wells with a Coulter Counter (Coulter Electronics, Hialeah, FL).
Western ligand blots. Unreduced conditioned medium samples (50 ,ul) were processed by SDS-PAGE using a 7.5-15% linear gradient, and separated proteins were electroblotted onto nitrocellulose filters (0. 45 ,gm pore size) using a BioTrans Unit (Gelman Sciences, Ann Arbor, MI). Filters were blocked, labeled with ['251 ]IGF overnight at 4°C, and visualized by autoradiography, according to the method ofHossenlopp et al. (27) . Unstained mol wt standards (BioRad, Richmond, CA) were processed in parallel, and proteins stained using India ink (28). Films were scanned with an UltroScan XL laser densitometer; absorbance curves were integrated and compared, and molecular size determined, using GelScan XL software (Pharmacia LKB Biotechnology Inc., Piscataway, NJ).
IGF-I receptor binding. Confluent fibroblast cultures (24-multiwells) were washed twice and the medium changed to SFM with or without IGF-I and [QAYL]IGF-I for 24 h. Cells were then incubated in 2 ml SFM at 37°C for 1 h (medium changed after 30 min) to allow dissociation of reversibly bound peptide (26 (30, 32) . Reduced (+100 mM DTT) samples were fractionated by SDS-PAGE. Unstained mol wt standards were processed in parallel. Gels were stained with Coomassie blue, dried, and exposed to Kodak XAR-2 film.
Statistics. Differences between two groups were analyzed using Student's t test for two independent samples. Results were considered statistically significant when P < 0.05.
Results
Characterization ofIGFBPs secreted by SV40-transformed and normal human fibroblasts: regulation by IGF-I. We incubated SV40-transformed human fibroblasts (SV40-HF) and nontransformed HF with or without hormonal additions, and collected serum-free conditioned medium after 24 h. Fig. 1 shows the migration of IGFBPs after SDS-PAGE of medium samples under nonreducing conditions, transfer of proteins onto nitrocellulose, and incubation with radiolabeled IGF-I. Medium from unstimulated SV40-HF contained IGFBPs with apparent mol wt of 42, 38, 28, and 24 kD. Western ligand blots of medium conditioned by the untransformed parent line also showed bands at 42, 38, 28, and 24 IGF-I (10 nM) increased levels of IGFBP-3 in medium from SV40-HF and normal HF cultures ( Fig. 1 and Table I ). As was more evident in the SV40-HF cells, IGF-I preferentially increased the 38-kD IGFBP-3 form (7-fold) over the 42-kD form (2.5-fold). IGF-I also increased 28-32-kD IGFBPs, and induced the appearance of a 36-kD IGFBP in these cells. Incubation with IGF-I had no significant effect on the 24-kD IGFBP form secreted by SV40-HF. The small increase in SV40-HF cell number with IGF-I treatment (122±7%; mean±SE, n = 9) was inadequate to account for the marked changes in secreted IGFBP-3 and 36 kD IGFBP. Furthermore, insulin (1,000 nM) had equivalent stimulatory effects on SV40-HF replication (122+14%, n = 5), but had no effect on IGFBP secretion. In normal adult HF ( Fig. 1 and Table I ), addition of IGF-I (10 nM) caused smaller relative increases in 38-kD (210%) and 42-kD (139%) IGFBP-3 forms. In these cells, IGF-I increased the 28-and 36-kD IGFBPs threefold and fivefold, respectively, and decreased levels ofthe 24-kD IGFBP by 80%. The 30-32-kD IGF-II-preferring IGFBP was also increased 50-100% by IGF-I treatment of SV40-HF and normal HF, as assessed by Western ligand blotting ofthe medium with radiolabeled IGF-II (data not presented). In three separate dose-response experiments, an effect of IGF-I to alter IGFBP release in normal HF and SV40-HF was evident at 0.1-1 nM IGF-I, and maximal at 5 nM IGF-I; insulin at 0.1-1,000 nM had no effect (data not shown). GH (1 ytg/ml) had little or no effect on IGFBP secretion in SV40-HF ( Fig. 1 and Table I ). In normal adult human fibroblasts there was a small but significant increase in 38-kD IGFBP-3 with GH treatment, in agreement with our earlier report (24) . GH did not block IGF-I-induced changes in IGFBP secretion in these cells (data not shown). The relative changes in the different IGFBP species with IGF-I, insulin, and GH treatment of SV40-HF and normal HF cultures are given in Table I .
These data indicate that IGF-I is a major regulator of its own binding proteins in normal and SV40-transformed HF cultures. We next investigated the mechanism(s) of the IGF-Iassociated increase in IGFBPs in these cells.
Is the IGF-I-specific increase in IGFBPa receptor-mediated event? As shown in Fig. 2, SV40-HF (2, 26, 30) . Thus, these data suggested that the IGF-I-stimulated increase in IGFBPs might not be receptor-mediated. In concordance with this, aIR-3, a monoclonal antibody that inhibits IGF-I binding and receptor-mediated action in human fibroblasts (29, 32) , inhibited IGF-I receptor binding but failed to block the IGF-I-induced changes in IGFBPs in normal HF and SV40-HF media (Fig. 3) . Furthermore, there were major differences in the ability of IGF-I, IGF-II, and different IGF-I analogues to stimulate IGFBP secretion (Figs. 4 and 5) . IGF-II, with 600-fold reduced affinity for IGFBPs (37) Changes in receptor availability were reflected in cell responsiveness to IGF-I (Fig. 6 B) . Preincubation with [QAYL]-IGF-I for 24 h caused a dose-dependent decrease in IGF-Istimulated [3H]thymidine incorporation in normal HF; after exposure to 1 nM [QAYL]IGF-I, cell responsiveness was only 35% ofcontrol. This relatively resistant state was also seen after a 48-h preincubation period and persisted for more than 24 h after removal of the [QAYL]IGF-I (data not shown). In contrast, preincubation with equivalent concentrations of IGF-I had no significant effect on subsequent cell responsiveness to IGF-I. IGF-I-stimulated [3H]AIB uptake in human fibroblasts was also impaired after preincubation with 1 nM [QAYL]IGF-1 (62±5% of maximum stimulation, n = 3, P < 0.05), whereas cells maintained responsiveness to IGF-I after incubation for 24 h with 1 nM IGF-I (91±5% of maximum stimulation, P = NS).
Discussion
IGF-I stimulates a marked increase in IGFBPs in the medium of normal and SV40-transformed human fibroblasts, independent oftype I IGF receptor binding. The results ofthese in vitro studies reflect observations of IGF-I-associated changes in IGFBPs in vivo (10) (11) (12) , and provide a possible mechanism to explain why extracellular fluid concentrations of IGF-I and specific IGFBPs are coordinated. Furthermore, our physiological studies suggest that direct IGF-I alteration of IGFBP availability provides a unique mechanism for modulating cellular responsiveness to IGF-I.
Human fibroblast IGFBPs: regulation by IGF-I. The
IGFBPs identified in human fibroblast conditioned medium (with apparent mol wt of 42/38, 36, 30-32, 28, and 24 kD) correspond to specific forms found in human serum (39, 40) .
The 42/38-kD doublet represents glycosylation variants of IGFBP-3 (34) . As demonstrated in this study, IGF-I increased 42/38-kD IGFBP-3 in the media of normal HF and SV40-HF, whereas GH had little or no effect. These results support the proposal put forth by us (13) and by others (10, 11, 17) that the apparent GH-dependency ofIGFBP-3 is mediated in large part by IGF-I. IGF-I's effect was particularly evident in SV40-HF cultures, which have low levels of medium IGFBP-3 in the unstimulated state. In these cells, there was a preferential increase in the 38-kD (7-fold) over the 42-kD (2.5-fold) variant, suggesting that degree of glycosylation may be an important characteristic of this regulation. Relative increases in 38-and 42-kD IGFBP-3 with the addition of IGF-I to normal HF cultures were 210 and 140%, respectively; the diminished sensitivity presumably reflecting the high basal secretion of IGFBP-3 by these cells. The absolute increase in IGFBP-3 in the medium supplemented with IGF-I may be similar in both normal and SV40-HF fibroblast systems, however. Martin and Baxter also reported an increase in IGFBP-3 with IGF-I in neonatal human fibroblasts (15) . These results in cultured human fibroblasts correspond to in vivo studies where infusion of hypophysectomized and diabetic rats and healthy man with IGF-I resulted in increased circulating IGFBP-3 (10, 12) . Also, circulating levels of IGF-I and IGFBP-3 change in parallel under a variety of pathophysiological conditions (11) . It may be relevant that within the plasma 150-kD IGFBP-3 complex, the 38-kD IGFBP-3, but not the 42-kD, form decreases with age (41) . Thus, normal HF and SV40-HF provide versatile models for examining possible underlying mechanism(s) for IGF-I regulation of IGFBP-3.
We also found that treatment of SV40-HF and normal HF with IGF-I resulted in increased 36-kD IGFBP, and had significant stimulatory effects on IGFBPs with mol wt in the range of 28-32 kD. In addition, IGF-I markedly decreased 24-kD IGFBP in normal HF. The specific identities of these IGF-Iregulated IGFBPs were not determined in this study. Nevertheless, our observations may be related to other in vivo and in vitro studies. IGF-I-"inducible" 28-32-kD IGFBPs have been described in fetal and neonatal human fibroblast cultures (15, 42) , rat osteoblast-like cells (18) , rodent muscle cells (14) , and rabbit articular chondrocytes (16) . The 36-kD IGFBP may represent 36-kD human IGFBP-2, which is increased in plasma during subcutaneous infusion of IGF-I in healthy adults (12) . However, in contrast to results in vivo where the increase is prevented by simultaneous GH administration (12) , GH in our study had no effect on basal or IGF-I-stimulated increases in IGFBPs. This difference in modulation by GH may indicate an indirect effect of GH in vivo. On the other hand, the 36-kD IGFBP in human fibroblast conditioned medium may be related to IGFBP-3, because these two forms appear to respond in concert to IGF-I. The 24-kD IGFBP most likely relates to IGFBP-4 purified from rat serum and human bone cell-conditioned medium (9, 43) . The IGF-I-associated decrease in 24-kD IGFBP described here in normal adult HF has also been reported by Clemmons et al. in human fetal fibroblasts (44) . In our study, IGF-II was twice as effective as IGF-I in decreasing medium levels of24-kD IGFBP. We did not observe a decrease in 24-kD IGFBP with IGF-I or IGF-II in SV40-HF cultures, and the potential significance of these differing results with transformation is unclear.
Mechanism: receptor-independent. Many peptide hormones have been shown to regulate IGFBP secretion through receptor-mediated changes in gene expression (45) (46) (47) (14) .
Physiological significance. What are the possible physiological implications of a receptor-independent mechanism allowing for a rapid increase in soluble IGFBP in the microenvironment as a direct response to IGF-I? Many peptide hormones, including IGF-I, insulin, and GH are able to induce a decrease in the number oftheir cell-surface receptors (downregulation), rendering the cells refractory to further stimulation (26, 49) . Insulin and GH are secreted in a pulsatile fashion and generally circulate at low levels. Total circulating IGF concentrations, on the other hand, are high and relatively invariable (50) and could result in extensive downregulation of the type I IGF receptor based upon in vitro studies (26) . However, the 1 50-kD IGFBP complex in serum restricts access of IGFs to the extravascular spaces and prevents the insulin-like effects of excess IGFs (10, 39); a similar role may exist for cell-derived IGFBPs. We and others have shown that soluble IGFBPs can prevent IGF-I receptor interaction (19) (20) (21) . In this study, we demonstrated that incubation of normal HF and SV40-HF with an IGF-I analogue unable to increase soluble IGFBPs, but having normal type I IGF receptor binding, occupied and downregulated the receptor more effectively than native IGF-I. This downregulation of the type I IGF receptor was paralleled by decreased responsiveness ofthe cells to subsequent IGF-I stimulated DNA synthesis and amino acid uptake. Moreover, addition of pure IGFBP-3 blocks IGF-I-induced receptor downregulation and cell desensitization in cultured bovine fibroblasts (51) . Ernst and Rodan also showed that enhanced IGF-I-stimulated DNA and collagen synthesis correlated with accumulation of IGFBP-3 in the culture medium (52) . Therefore, an acute increase in soluble IGFBPs, especially IGFBP-3, may be a "reflex" response of specific cells to changes in local IGF-I levels, allowing continued cell responsiveness.
In addition, an increase in soluble IGFBPs may capture and retain the IGF-I peptide in the cell microenvironment, and act as a time-release complex. Blum et al. reported that addition of IGFBP-3 enhanced IGF-I-stimulated thymidine incorporation in baby hamster kidney fibroblasts (53) . Although cell surface association was not determined in their study, it is conceivable that IGF-I activates or facilitates IGFBP-3 attachment to spe-cific cell membranes. This process would be analogous to the assembling of the 1 50-kD plasma complex, i.e., the acid-labile subunit binds only IGFBP-3 complexed with IGF (54). Thus, IGF-I regulates the availability ofIGFBPs in cultured human fibroblasts by a unique receptor-independent mechanism. Changes in levels of soluble IGFBPs, in turn, modulate IGF-I peptide and receptor interaction and may constitute an important level of control in IGF cellular physiology. Further studies are needed to characterize this mechanism, and to determine its contribution to IGF pathophysiology and its implication in the clinical use of IGFs.
